Episurf Medical appoints Dr Michael Manley special advisor for US strategy

Episurf Medical (NASDAQ: EPIS B) today announced that it has appointed Dr Michael Manley as special advisor in support of its US strategy. 

Professor Leif Ryd, Senior Medical Advisor to Episurf Medical says: “Michael Manley has held leading positions in the orthopaedic industry within research and development for more than 30 years. He knows every detail in implant development."

Dr Manley has been with Stryker Orthopaeidcs since 1987, was Chief Scientific Adviser until December 2016 and remains a consultant to the company in certain areas. After three decades, Dr Manley has extensive experience in the fields of clinical studies, regulatory processes and procedures along with research and developmental science. 

Pål Ryfors, CEO of Episurf Medical says: “We are forming a team to develop our US strategy. We are enormously happy for the opportunity to work with Dr Manley as an advisor to our team. Dr Manley's background and experiences are unparalleled. He will advise the Episurf team during this important strategic step in devevlopment of our company.” 

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical 

Tel: +46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on 7 June 2017.